| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| PLUS THERAPEUTICS Inc. | REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-GBM) | Glioma | Phase 2 | Ongoing | Intracerebral | Oncology |
| PLUS THERAPEUTICS Inc. | DocePLUS (ATI-1123) | Platinum-sensitive small cell lung cancer | Phase 2 | Intravenous | Oncology | |
| PMGC Holdings Inc. | Exosomes | Hairloss | Phase 2 | Data Released | Intravenous | N/A |
| PMGC Holdings Inc. | EL-22 (BLS-M22) | GLP-1 Weight Loss Drugs and Age-Related Sarcopenia | Phase 2 | Trial Planned | Intravenous | Endocrinology |
| PMV Pharmaceuticals Inc. | Rezatapopt (PC14586) - (PYNNACLE) | Solid tumors | NDA Filing | Ongoing | oral | Oncology |
| PolyPid Ltd. | D-PLEX100 - (SHIELD II) | Surgical Site Infection | NDA Filing | Data Released | Intraperitoneal | Wound Care |
| PolyPid Ltd. | D-PLEX100 | Sternal (bone) sternal surgical site infections | Phase 3 | Clinical Pause | Intratumoral | Wound Care |
| PolyPid Ltd. | D-PLEX100 - (SHIELD I) | Abdominal (soft tissue) sternal surgical site infections | Phase 3 | Data Released | Intraperitoneal | Wound Care |